Related Experiment Videos
Melanoma antigens recognised by CD8+ and CD4+ T cells
1Departments of Surgery and Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pennsylvania, USA.
Forum (Genoa, Italy)
|September 29, 2000
Summary
Melanoma immunotherapies using tumor antigens and peptides have advanced significantly. These vaccines boost T cell responses against cancer, showing promise for effective melanoma treatment.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Significant progress in melanoma immunobiology over the last decade.
- Identification of numerous tumor-expressed antigens recognized by patient T cells and immunoglobulins.
Purpose of the Study:
- To review the advancements in melanoma immunotherapies utilizing tumor antigens and peptides.
- To highlight the potential of these approaches in augmenting anti-melanoma T cell responses.
Main Methods:
- Integration of identified tumor antigens, derivative peptides, or analogues in vaccine trials.
- Focus on augmenting melanoma-specific CD4+ and CD8+ T cell responses.
Main Results:
- Melanoma peptide-based immunotherapies targeting CD8+ cytotoxic T lymphocytes have demonstrated clinical efficacy.
- Combinations with T cell growth factors or dendritic cells enhance success.
Conclusions:
- Vaccine strategies incorporating poly-epitope and CD4+ T cell-recognized peptides are expected to improve clinical outcomes.
- These approaches promote a diversified T cell repertoire against tumors.